Ranbaxy Laboratories has dipped 7% at Rs 442 after the company signed  the consent decree with the US Food and Drug Administration (USFDA) last month and filed with the Department of Justice in federal court in Maryland on January 25 requires Ranbaxy to relinquish 180-day marketing exclusivity for three pending generic drug applications.

According to reports, India’s biggest drugmaker, may forgo at least $200 million (approx Rs 1,000 crore) in sales as a result of a proposed settlement with U.S. authorities over manufacturing violations.

A combined 30,000 shares have changed hands on the counter on the NSE and BSE.